Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T13:23:43.876Z Has data issue: false hasContentIssue false
  • English
  • Français

Managing the patient with depression and anxiety

Published online by Cambridge University Press:  16 April 2020

DL Dunner  and
GC Dunbar
DL Dunner
Affiliation:
Department of Psychiatry and Behavioral Sciences, University of Washington, Suite 306, 4225 Roosevelt Way NE, Seattle, Washington98105, USA
GC Dunbar
Affiliation:
Department of Psychiatry and Behavioral Sciences, University of Washington, Suite 306, 4225 Roosevelt Way NE, Seattle, Washington98105, USA
Get access

Summary

The effect of paroxetine on symptoms of anxiety associated with depression were assessed by meta-analysis of data on the use of paroxetine (n = 2963), active control (n = 1151), and placebo (n = 554) in six-week clinical trials. Paroxetine significantly reduced psychic anxiety by comparison with placebo from week 1 and was more effective than active control from week 2. Paroxetine improved somatic anxiety from week 4 of treatment. There was no association between antidepressant therapy and the emergence of anxiety symptoms in patients with little or no baseline anxiety. Paroxetine resolved baseline symptoms of agitation from week 1 of treatment, and both paroxetine and active control prevented the emergence of agitation. There was no difference between placebo and antidepressant therapy in the frequency of adverse events indicative of increased arousal. The results indicate the utility of paroxetine in depressed patients presenting with associated anxiety symptoms.

Keywords

paroxetineanxietydepression
Type
Research Article
Information
European Psychiatry , Volume 8 , Issue S1: New perspectives in the pharmacological treatment of depression. Defining the ideal antidepressant. 3 November 1992, Barcelona, Spain , 1993 , pp. 9s - 12s
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Clayton, PJGrove, WMCoryell, WKeller, MHirschfeld, RFawcett, J (1991) Follow-up and family study of anxious depression Am J Psychiatry 148, 1512–1517Google ScholarPubMed
Dunbar, GCCohn, JBFabre, LFFeighner, JPFieve, RRMendels, JShrivastava, RK (1991) A comparison of paroxetine, imipramine, and placebo in depressed outpatients Br J Psychiatry 159, 394–398CrossRefGoogle Scholar
Gorman, JMLiebowitz, MRFyer, AJGoetz, DCampeas, RBFyer, MRDavies, SOKlein, DF (1987) An open trial of fluoxetine in the treatment of panic attacks J Clin Psychopharmacol 7, 329–332CrossRefGoogle ScholarPubMed
Hamilton, M (1988) In: Handbook of Anxiety Disorders (Last, CAHersen, M eds). Pergammon Press, New York, 143Google Scholar
Jenner, PN (1992) Paroxetine: an overview of dosage, tolerability and safety Int Clin Psychopharmacol 6 (suppl 4), 69–80CrossRefGoogle ScholarPubMed
Kerr, JSSherwood, NHindmarch, I (1991) The comparative psychopharmacology of 5HT-reuptake inhibitors Hum Psychopharmacol 6, 313–317CrossRefGoogle Scholar
Montgomery, SA (1989) New antidepressants and 5-HT uptake inhibitors Acta Psychiatr Scand 80 (suppl 350), 107–116CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.